Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Multiple Myeloma 430Lymphoma, Large B-Cell, Diffuse 97Leukemia, Lymphocytic, Chronic, B-Cell 88Lymphoma, Follicular 81Recurrence 72Lymphoma 62Lymphoma, Mantle-Cell 59Neoplasms, Plasma Cell 58Lymphoma, B-Cell, Marginal Zone 47Lymphoma, Non-Hodgkin 46Leukemia, Myeloid, Acute 34Leukemia 32Neoplasms 24Myelodysplastic Syndromes 24Lymphoma, B-Cell 24Waldenstrom Macroglobulinemia 18Hodgkin Disease 18Smoldering Multiple Myeloma 17Lymphoma, T-Cell, Peripheral 16Burkitt Lymphoma 14Hematologic Diseases 13Lymphoma, T-Cell, Cutaneous 12Lymphoma, T-Cell 12Prostatic Neoplasms 11Precursor Cell Lymphoblastic Leukemia-Lymphoma 11Sezary Syndrome 10Mycosis Fungoides 10Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 9Lymphoma, Large-Cell, Anaplastic 9Leukemia, Myelomonocytic, Chronic 9

Interventions

trametinib 1spartalizumab 1pembrolizumab 1motesanib diphosphate 1lenvatinib 1gallium Ga 68 dotatate 1dabrafenib 1cediranib 1Sorafenib 1Sodium Iodide 1Lenalidomide 1Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Thyroid cancer, Hurthle cell × Lenalidomide × Clear all
NCT01208051 2021-07-15

Cediranib Maleate With or Without Lenalidomide for the Treatment of Thyroid Cancer

National Cancer Institute (NCI)

Phase 1/2 Completed
127 enrolled 18 charts
EndocrineHead & Neck

Thyroid cancer, Hurthle cell, Thyroid Cancer, Papillary, Adenocarcinoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡